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Abstract 
Purpose: To compare the health-related quality of life (HRQOL) of Chinese patients with 
prostate cancer against the general population and patients with colorectal cancer, breast cancer, 
nasopharyngeal cancer and leukaemia. 
Methods: Chinese male patients (n=291) with a confirmed diagnosis of prostate cancer were 
recruited from a urological specialist outpatient clinic in Hong Kong. HRQOL was measured by 
a condition-specific Functional Assessment of Cancer Therapy-Prostate (FACT-P) and a generic 
Chinese (HK) SF-12 Health Survey Version 2 (SF-12v2) questionnaire. Mean HRQOL scores of 
condition-specific and generic questionnaires were compared to available scores derived from 
other cancers and age-matched male general population, respectively. 
Results: Chinese patients with prostate cancer had lower General Health and Vitality domains 
and lower Mental Component Summary scores than the age-matched Hong Kong normative 
population. Patients with prostate cancer reported better condition-specific HRQOL (physical 
well-being, emotional well-being and function well-being) when compared to general cancer 
population, patients with breast cancer, colorectal cancer, nasopharyngeal cancer and leukaemia 
in Hong Kong. 
Conclusions: Patients with prostate cancer substantially perceived their HRQOL to be better, 
compared to patients with other cancers, with overall health, energy and mental health below of 
Hong Kong general population. Interventions should target at these domains in order to improve 
the HRQOL of patients with prostate cancer. It is reassuring to find that prostate cancer had less 
negative impact on HRQOL than other cancer types did.  
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Manuscript Text 
Introduction  
According to the worldwide burden of cancer study in 2008, prostate cancer is the second most 
frequently diagnosed cancer in men [1]. 93% have a prognosis for prolonged survival for at least 
5 years and 72.1% for at least 10 years [2]. Due to the effectiveness of prostate specific antigen 
screening, nowadays, early detection of prostate cancer and curative treatments can decrease 
prostate cancer-speciﬁc mortality [3]. Since many patients with prostate cancer survive for 
prolonged periods, the impact of illness and its treatments on patients’ daily life are an important 
outcome of interest for clinicians. Quantitative and qualitative studies suggested that the impact 
of prostate cancer are multifaceted including, but not limited to, sexuality, urinary and bowl 
functions, physical functioning and mental health, to the detriment of health-related quality of 
life (HRQOL) [2,4-7].   
To date, evidence about the HRQOL of patients with prostate cancer has been inconclusive or 
lacked generalizability. A study in Japan found that cancer stage was not a factor associated with 
HRQOL [8] while a study in the US found that patients with advanced cancer stage had poorer 
HRQOL [9]. The Chinese are a major population of interest representing 20% of the global 
population.  However, to date, information about the impact of prostate cancer on HRQOL is 
lacking. Several comparative studies [10,5] assessed the differences in HRQOL between prostate 
cancer and general population but findings in western populations might not be transferrable to 
Chinese populations because (i) HRQOL is culturally specific [11] and (ii) the health belief of 
Chinese, which is strongly influenced by traditional Chinese medicine, is distinct from that of 
western populations [12]. The lack of knowledge about the impact of prostate cancer on the 
HRQOL of Chinese patients necessitates the present study.  Knowledge and understanding of the 
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impacts of prostate cancer on HRQOL can assist clinicians and policymakers to formulate 
interventions that target at specific HRQOL domains.  
The aim of this study was to evaluate the HRQOL of Chinese patients with prostate cancer. The 
specific objectives were (i) to compare the HRQOL of prostate cancer patients with that of the 
Hong Kong population norm by using a generic HRQOL measure; and (ii) to compare HRQOL 
between prostate cancer patients and other cancer patient populations by using a disease-specific 
HRQOL measure.   
Methods  
Study design and subjects 
This study was part of a prospective longitudinal study which evaluated the health status and 
HRQOL of Chinese patients with prostate cancer in Hong Kong. The baseline data of the study 
was used to evaluate the HRQOL of Chinese patients with prostate cancer.  The inclusion 
criterion was Chinese patients with confirmed diagnosis of prostate cancer. Subject who went to 
a urological specialist outpatient clinic of Queen Mary Hospital in Hong Kong between May 
2013 and January 2014 for medical follow-up appointment were recruited by convenience 
sampling.  Patients were excluded if they could not understand Cantonese, refused to participate 
or were too ill to give consent. Subjects who consented were asked to provide their contact 
details and were subsequently contacted by a trained interviewer who administered the study 
questionnaire by face-to-face interview.  The interviewer was required to read the study 
questionnaire verbatim in a standardized face-to-face interview approach. Details of patient 
recruitment data collection have been reported elsewhere[13].  
Study Instrument 
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The Chinese (HK) SF-12 Health Survey Version 2 (SF-12 v2) is a 12-item generic HRQOL 
instrument, which measures eight domains including physical functioning (PF), role limitation 
due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social 
functioning (SF), role limitation due to emotional problems (RE) and mental health (MH) [14]. 
Moreover, the SF-12 v2 can be summarized into physical and mental component summary (MCS) 
scores. The higher the SF-12 v2 scores, the better the HRQOL. The SF-12 v2 has been validated 
in Hong Kong general population and the population norm of the SF-12 v2 has been established 
for Chinese adults in Hong Kong [15,16]. Using the generic HRQOL instrument allows us to 
compare the HRQOL of our subjects to the age adjusted male population norm. 
The Functional Assessment of Cancer Therapy-Prostate (version 4) (FACT-P) is a 39-item 
prostate cancer-specific HRQOL instrument, which contains five subscales namely physical 
well-being (PWB), social/family well-being (SWB), emotional well-being (EWB), functional 
well-being (FWB) and prostate cancer subscale [17]. The PWB, SWB, EWB and FWB subscales 
are the core module of the Functional Assessment of Chronic Illness Therapy (FACIT), which is 
applicable to all cancer patients. The prostate cancer subscale is only applicable to patients with 
prostate cancer. The higher the FACT-P scores, the better the HRQOL. The instrument was 
administered to supplement the generic instrument because the condition-specific instrument is 
more sensitive in capturing the specific impact of prostate cancer on HRQOL [18]. Traditional 
Chinese version of FACT-P has shown to be valid and reliable for use in Hong Kong Chinese 
patients with prostate cancer [13]. 
Previous studies in Hong Kong also administered FACIT instrument to assess the condition-
specific HRQOL of cancer patients such as (i) general cancer patients [19], (ii) patients with 
nasopharyngeal carcinoma (NPC)  who underwent radiotherapy [20], (iii) patients with breast 
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cancer  [21], (iv) patients with colorectal cancer (CRC) [22] and (v) patients with acute 
leukaemia, chronic leukaemia, lymphoma and others [23]. Notably, three studies[19-21] 
conducted in early 2000s administered an earlier version (Version 3) of the FACIT instrument 
which subsequently underwent changes in item wording and scale structure to become the latest 
version (Version 4) of FACIT instrument. When comparing subscale scores between the two 
versions, EWB subscale was re-scored in Version 4 and not available for fair comparison.  
Data Analysis 
Independent t-test was used to assess the difference in mean SF-12 v2 domain and summary 
scores between subjects and age-matched  males from Hong Kong general population [16]. For 
such normative comparison in our study, we identified the same of matching subjects from the 
Hong Kong population norm study dataset [16] which has been utilized for normative 
comparisons in other disease[12,24] conditions. In other words, a match was defined as male 
subjects of the same exact age in year. The SF-12 v2 data were in-house data Besides, 
independent t-test was used to assess the difference in PWB, SWB, EWB and FWB scores 
between our patients and (i) general cancer patients (n=1108) [19], (ii) patients with NPC who 
underwent radiotherapy (n=211) [20], (iii) patients with breast cancer (n=259) [21], (iv) patients 
with CRC (n=286) [22], and patients with acute leukaemia, chronic leukaemia, lymphoma and 
others  (n=134) [23] reported in other studies sampling in Queen Mary Hospital, Hong Kong. 
These data about the HRQOL of cancer patients were all obtained from published manuscripts.  
In order to further understand the impact of prostate cancer treatment on HRQOL, we compared 
the SF-12 v2 scores between Hong Kong general population and different types of treatment, and 
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the FACT-P scores between different types of treatment by one-way ANOVA with Tukey’s 
HSD test.   
Cohen’s d effect size was calculated to estimate the clinical significance of HRQOL differences. 
According to the suggestion by Sloan et al, the 1/2 standard deviation is a conservative estimate 
of an effect size that is likely to be clinically meaningful [25]. Cohen’s d effect size 0.5 means 
that the two means are 1/2 standard deviation apart [26].  
Ethics approval  
The study protocol was approved by the institutional review boards: HKWC (Ref No.: UW13-
239). 
Results  
A total of 339 patients with prostate cancer were invited to join the study. Of the 339 patients, 29 
patients refused to participate. A further 19 patients were excluded because of hearing problems, 
inability to communicate in Chinese/Cantonese, cognitive impairments or being too ill to 
complete the questionnaire. Among them, 291 eligible subjects (response rate: 85.9 %) were 
included in HRQOL assessment.  Table 1 shows the socio-demographics and clinical 
characteristics of prostate cancer patients. 35.05 % of subjects completed radical prostatectomy, 
40.21 % of subjects completed androgen deprivation/ combined androgen blockade, 15.46 % of 
subjects completed radical curative radiation, 2.75 % of subjects completed adjuvant radiation 
and 1.37 % of subjects completed chemotherapy at the time of subject recruitment. Concerning 
HRQOL data complete rate, all subjects (100%) completed FACT-P whilst 289 subjects (99.3%) 
completed SF-12 v2.  
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Table 2 shows the means and the standard deviations (SD) of the SF-12 v2 scores and their 
comparison with normative population in Hong Kong. The SF-12 v2 GH, VT, and MCS scores 
of our subject lower than the adjusted population norms (p-value <0.01), with effect size ≥0.5. 
Although the MH scores of out subjects were lower than the adjusted population norms (p-
value<0.01), the effect size was smaller than 0.5, which was probably not clinically significant. 
Furthermore, the SF-12 v2 PF score of our subjects was significantly higher than the adjusted 
norm (p-value <0.01) but the effect size was only 0.40, which was probably not clinically 
significant. 
Table 3 shows the FACT-P scores of prostate cancer patients and their comparison with patients 
with other cancer types. Overall, prostate cancer patients had better physical well-being (p-value 
<0.05, effect size =0.61) and functional well-being (p-value <0.05, effect size =1.07) than 
general cancer patient populations in Hong Kong. Moreover, prostate cancer patients perceived 
better physical well-being than patients with leukaemia (p-value<0.05, effect size =0.59). 
Prostate cancer patients perceived better emotional well-being than patients with leukaemia 
patients (p-value<0.05), with effect size 0.71. Prostate cancer patients perceived better functional 
well-being than patients with NPC who underwent radiotherapy or breast cancer patients (p-
value<0.05), with effect size >0.5. 
Besides, we found that prostate cancer patients perceived better physical well-being than patients 
with breast cancer (p-value<0.05) but poor physical well-being than CRC patients (p-
value<0.05), but the effect size statistics were both smaller than 0.5, which was probably not 
clinically significant. There was no statistically significant difference in social well-being among 
different cancer patients, except for breast cancer patients who had better social well-being than 
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prostate cancer patients (p-value<0.05). However, the small effect size (0.17) was probably not 
clinically significant. 
Sub-group analysis by one-way ANOVA found no statistical difference (p-value >0.05) in any 
SF-12 scores between Hong Kong population and subjects in different treatment groups. 
Furthermore, there was no statistical difference in PWB, SWB, EWB and FWB scores among 
subjects in different treatment group. The post hoc analysis found that subjects who underwent 
radical curative radiation (mean: 33.1, SD: 9.0) had poorer HRQOL as measured by prostate 
cancer subscale of the FACT-P than those who underwent radical prostatectomy (mean 37.0, SD: 
5.1) with effect size 0.53 (p-value=0.015).  
Discussions 
To the best of our knowledge, it was the first study to examine the generic and disease-specific 
HRQOL of general prostate cancer patients in the Chinese population. We recruited patients with 
a wide range of clinical characteristics, instead of patients undergoing a specific treatment, in 
order to strengthen the external validity of our study findings.   
The impact of prostate cancer on HRQOL measured by the SF-12 v2 
Our prostate cancer subjects had poorer HRQOL in MCS with moderate effect sizes (Cohen’s d 
effect size >0.5) than the adjusted population norms. It appears the prostate cancer had more 
negative impacts on the mental components than on the physical components of HRQOL. A 
previous study in the US found that people with prostate cancer had poorer HRQOL in all 
domains as measured by the SF-12 [5]. The study also found the MCS was much lower than the 
norm (9.2 out of 100-point), compared with the PCS (2.3 out of 100-point) [5], implying that 
prostate cancer substantially jeopardized mental well-being over that of physical well-being. 
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Psychological distress is evident throughout the course of prostate cancer [2,27,28]. A recent 
systematic review and meta-analysis by Watts found that both anxiety and depression were 
prevalent throughout the course of prostate cancer [29]. Another systematic review by Dale 
found that 10-36 % of males with prostate cancer had anxiety [30]. A study by Korfage found 
that 27 % of prostate cancer patients have depression [31]. Patients with prostate cancer might be 
concerned about metastasis and the side effects of treatments.  
In addition to the mental aspects of HRQOL, our subjects had poorer HRQOL in the GH and VT 
domains with moderate effect sizes (Cohen’s d effect size >0.5) than the adjusted population 
norms. It is probably because treatments for prostate cancer such as androgen deprivation 
therapy often have side effects causing reduced energy, sexual dysfunction and loss of bone and 
muscle mass [32,33]. Besides, our findings were consistent with the findings of a previous study 
on Chinese patients with lower urinary tract symptoms (LUTS) which found that Chinese 
patients with LUTS had poorer HRQOL in the VT and GH domains with moderate effect sizes 
than the adjusted population norms [12]. The presenting symptoms of prostate cancer are similar 
to those of LUTS. Furthermore, according to traditional Chinese medicine, urological and 
reproductive diseases are always associated with “kidney qi and yang deficiency”, which also 
lead to the deterioration of masculinity, energy and overall health function in males [12,34,35]. 
People with prostate cancer might perceive that their general health and sexual function declined, 
which lead to poorer HRQOL in GH and VT domains. We also found that the VT score of 
prostate cancer patients was 13.73-point lower than the adjusted population. Decrease in vitality 
is disabling. Previous study found that a 10-point reduction in VT score of the SF-36 would 
increase the risk of inability to work due to fatigue, job loss at one year, hospitalization at one 
year and short-term (0-18 months) and long-term (19 months or more) mortality [36]. 
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Paradoxically, the PF domain of the subjects was better with a moderate effect size 0.40 although 
the effect size was smaller than 0.5, which was probably not clinical significant. This finding was 
similar to that found in Japan [8]. It was hard to explain why the PF score in patients with 
prostate cancer were higher than that of the population norm. One possible explanation is the 
“response shift theory” [37].  Prostate cancer patients might reframe their expectation for their 
activity of daily living, which in turn leads to changes in the internal standard about physical 
functioning. As a result, they might have “better” PF scores than the corresponding norm.  
Further studies are required to confirm this finding and to explore the underlying reason. 
Condition-specific HRQOL between prostate cancer and other cancers 
We found that patients with prostate cancer had better condition-specific HRQOL than the 
general cancer population in Hong Kong, especially for the physical and functional aspects. 
Moreover, compared with patients with breast cancer, CRC, NPC or leukaemia in Hong Kong, 
our subjects had better condition-specific HRQOL. The findings are reassuring.  It was possible 
that prostate cancer is relatively “indolent” with a slow progressive course and consequently, 
when compared with other cancer types, prostate cancer may have a less aggressive impact on 
patients’ HRQOL. Furthermore, compared with the side effects of the treatment for other cancer 
types such as radiotherapy for NPC patients and mastectomy for breast cancer, those for prostate 
cancer such as watchful waiting and hormonal therapy are less aggressive. Studies have 
suggested that HRQOL is greatly impaired by leukaemia because of aggressive treatments [38] 
and complication of bone marrow transplantation [39]. Data about the comparison of different 
cancer types are not well documented, which calls for the need of comparison studies to examine 
HRQOL patterns among different cancer types.   
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Running Title: HRQOL of Chinese prostate cancer patients 
Page 13 of 24 
In regard to the Prostate Cancer Subscale, there was no difference (independent t-test p-value 
>0.05) in the subscale score between our study subject and the FACT-P validation sample (n= 96; 
mean score= 36.9, standard deviation= 6.6) recruited in the University of Chicago[17]. Actually, 
it is hard to compare our study findings with others because the study samples of the majority of 
studies were selective such as patients undergoing surgical intervention or hormonal therapy, and 
patients with watching waiting. The difference in clinical characteristics hinders comparison.  
The HRQOL and prostate cancer treatments 
Our subgroup analysis found no difference in the SF-12 v2 scores between age-adjusted Hong 
Kong population norm and subject in different treatment groups, and the FACT-G scores in 
subjects in different treatment groups. Our findings were consistent with those of previous 
studies [40-42]. A study on men with localized prostate cancer in the US found no difference in 
SF-36 and FACT-G scores between control group, surgery group, radiation group and watchful 
waiting group [40]. Another study in the US also found no difference in the SF-12 and FACT-G 
scores between control group, surgery group and radiation group[42]. There were some possible 
explanations. First, the SF-12 v2 is a generic HRQOL measure. The question items might not be 
specific and sensitive enough to capture of the impact of diseases or different treatments on 
HRQOL [43]. Furthermore, the FACT core module is applicable for all cancer patients. 
Therefore, it might contain irrelevant domains and may miss specific concerns held by our 
prostate cancer patients.  Besides, the relatively small sample size in subgroup analysis might 
lead to insignificant results. Further studies with larger sample size are needed to confirm our 
findings.  
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On the contrary, our subgroup analysis found that subjects who underwent radical curative 
radiation had poorer HRQOL as measured by prostate cancer subscale of the FACT-P than those 
who underwent radical prostatectomy (3.9-point, with effect size 0.53). Based on the suggestion 
by Sloan et al [25], the 1/2 standard deviation (Cohen’s d effect size 0.5 [26]) is likely to have 
clinically meaningful difference. Furthermore, a previous study estimated that the clinically 
distinguishable score of the  prostate cancer subscale of the FACT-P ranged from 2 to 3-point 
[44]. Thus, the difference in HRQOL detected between two groups in the present study was very 
likely to be clinically meaningful.  
The study in the US found that subjects who underwent brachytherapy (mean: 33.2) tended to 
have poorer HRQOL as measured by the FACT-P prostate cancer subscale than those who 
underwent radical prostatectomy (mean: 37.8) [42]. A literature review suggested that there are 
more risks of urinary voiding difficulties and difficulties with bowel function for radiation 
treatment [45]. The study in the US also found that patients who underwent radiotherapy tended 
to have poorer irrigative urinary symptoms, bowel symptoms, sexual functions and obstructive 
voiding symptoms than those who underwent radical prostatectomy [42].  
Clinical implications and further studies 
Since patients with prostate cancer had poorer mental components of HRQOL, the anxiety and 
concern of patients with prostate cancer should be assessed and addressed. Counseling and 
pastoral care should be a part of routine care for patients with prostate care with close attention 
to the possibility of poorer HRQOL related to general health and energy. First, clinicians should 
educate Chinese patients about the etiology of prostate cancer and reorient Chinese patients that 
prostate cancer is not related to problems of the kidney but the reproductive system. Second, in 
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addition to treatments for prostate cancer, patients might also need some interventions about life 
style modification in order to improve their general well-being and energy. Furthermore, 
previous studies found that physical exercise such as resistance exercise can reduced fatigue and 
improve muscular fitness and HRQOL in men with prostate cancer [46,47]. 
Strengths and Limitations 
There are some strengths in the present study. First, most studies about the HRQOL of patients 
with prostate cancer were based on clinical trials. The selection criteria for subject recruitment 
limited the external validity of the study findings. Our study recruited patients with diverse 
clinical characteristics which makes our study findings more generalizable. Second, we used 
both generic and condition-specific HRQOL instruments, which provided a more comprehensive 
HRQOL assessment. Third, to our knowledge, it should be the first study to compare the FACT-
G scores among different primary tumor sites. Several limitations should be noted in the present 
study. First, historical comparison was conducted to compare the prostate cancer and general 
population groups that were not recruited during the same period of time. Second, due to the 
paucity of patient-level data of other cancer types, comparison of other cancer types did not 
match to minimize bias of differences in HRQOL between prostate cancer and other cancer types. 
Third, some factors such as mental health, health belief, socio-demographics were not collected 
in the present study [48,49]. Further studies should be explored the impacts of these factors on 
HRQOL in prostate cancer patients.   
Conclusion 
This preliminary study suggested that prostate cancer patients have poorer HRQOL, particularly 
in the GH domain, VT domain and mental component summary of the SF-12 v2 than the normal 
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population. It suggested that prostate cancer jeopardizes the overall health perception and mental 
health in Chinese patients. It is reassuring to find that compared with other cancer types, patients 
with prostate cancer had better HRQOL as measured by the condition-specific instrument. It 
might be due to the less aggressive nature of prostate cancer, relative to other cancers.  
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Table 1. Baseline socio-demographic and clinical characteristics  
Demographic Total (N=291) 
 
Clinical Total (N=291) 
Characteristics N % 
 
Characteristics N % 
Age (years, Mean±SD) 74.92 ± 8.61 
 
PSA 
  
Education 
    
<0.1ng/ml 109 37.46 % 
 
No formal schooling 46 15.81 % 
  
≥0.1 & <10ng/ml 121 41.58 % 
 
Primary 98 33.68 % 
  
≥10ng/ml 39 13.40 % 
 
Secondary 90 30.93 % 
  
Unknown 22 7.56 % 
 
Tertiary or above 53 18.21 % 
 
AJCC Cancer Staging 
  
 
Unknown 4 1.37 % 
  
I 58 19.93 % 
Marital Status 
    
II 75 25.77 % 
 
Married 222 76.29 % 
  
III 31 10.65 % 
 
Not married 65 22.33 
  
IV 112 38.49 % 
 
Unknown 4 1.37 % 
  
Unknown 15 5.15 % 
 
  
 
Distant metastasis 59 20.27 % 
Currently Working 
   
KPS 
  
 
Yes 25 8.59 % 
  
Mean±SD 91.39 ± 12.50 
 
No 262 90.03 % 
  
≤70 23 7.90 % 
 
Unknown 4 1.37 % 
  
80 34 11.68 % 
Monthly income (HKD$) 
    
90 64 21.99 % 
 
≤20,000 238 81.79 % 
  
100 138 47.42 % 
 
>20,000 49 16.84 % 
  
Missing 32 11.00 % 
 Unknown 4 1.37 %  Treatments #   
      
Watchful waiting/ active 
surveillance 
24 8.25 
      Radical prostatectomy 102 35.05 
      
Androgen deprivation/ 
Combined androgen 
blockade 
117 40.21 % 
      Radical curative radiation 45 15.46 
      Adjuvant radiation 8 2.75 
      Chemotherapy 4 1.37 
SD=standard deviation;  
PSA=Prostate-specific antigen;  
KPS=Karnofsky performance status; AJCC=American Joint Committee on Cancer 
# It shows the treatments that patients have undergone. Some patients might have received more than one treatment. 
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Table 2: the SF-12 v2 scores of study subjects 
 
Subjects with Prostate 
Cancer + 
Age-sex adjusted HK norm 
[16] +   
SF-12 v2 scores n=142 n=142     
 
Mean (SD) Mean (SD) 
 
Effect size ^ 
Physical Functioning 84.33 (25.20) 73.06 (30.95) * 0.40 
Role Physical 79.14 (27.28) 75.97 (25.40) 
 
0.12 
Bodily Pain 81.16 (25.30) 79.58 (24.48) 
 
0.06 
General Health 48.80 (30.81) 63.49 (26.36) * 0.51 
Vitality 60.92 (31.15) 74.65 (22.87) * 0.50 
Social Functioning 82.75 (25.82) 80.46 (23.65) 
 
0.09 
Role Emotional 83.45 (22.41) 86.00 (20.55) 
 
0.12 
Mental Health 71.65 (21.00) 81.51 (19.51) * 0.49 
Physical Component Summary score 48.82 (10.63) 46.10 (12.56) 
 
0.23 
Mental Component Summary score 52.08 (10.16) 57.45 (9.80) * 0.54 
SD=standard deviation; AJCC=American Joint Committee on Cancer 
*Significant difference between subjects with prostate cancer (overall) and HK norm[16] (P< 0.01). 
+of 2763 respondents in the study of the population norm of the SF-12 v2, only 142 respondents could match our study subjects 
(by age and sex) [16]. 
^ Cohen's d  effect size was calculated as the difference between mean scores, divided by pooled SD. 
# of those who had AJCC staging, one subjects did not complete SF-12 v2  
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Table 3: the FACT-P scores of study subjects   
  
Prostate 
cancer 
General Cancers [19] 
Nasopharyngeal carcinoma 
[20] 
Breast Cancer [21] Colorectal cancer  [22] Leukaemia [23] 
 
n=291 n=1108  n=211 n=259 n=286 n= 134 
FACT –P 
scores 
Mean (SD) Mean (SD) Effect size ^ Mean (SD) Effect size ^ Mean (SD) Effect size ^ Mean (SD) Effect size ^ Mean (SD) Effect size ^ 
Physical Well-
Being  
24.63 (3.64) 21.80 (5.50)* 0.61 24.00 (4.00) 0.16 23.07 (4.87)* 0.36 25.62 (3.09)* 0.29 22.1 (4.8)* 0.59 
Social/Family 
Well-Being  
19.62 (5.18) 19.30 (4.60) 0.07 19.60 (4.40) 0.00 20.48 (4.97)* 0.17 20.17 (4.34) 0.12 20.4 (5.3) 0.15 
Emotional 
Well-Being # 
21.08 (3.76) N/A N/A N/A N/A N/A N/A 21.40 (2.82) 0.10 18.3 (4.1)* 0.71 
Functional 
Well-Being  
19.72 (5.38) 13.70 (5.90)* 1.07 16.00 (5.40)* 0.69 15.42 (6.12)* 0.75 19.03 (4.38) 0.14 19.2 (5.3) 0.10 
Prostate Cancer 
Subscale 
35.82 (6.61) N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
SD=standard deviation; AJCC=American Joint Committee on Cancer 
* independent t-test was used to compare the scores between two groups (p<0.05) 
^ Cohen's d effect size was calculated as the difference between mean scores, divided by pooled SD. 
# Those studies used FACT-G (version 3). The composition of emotional well-being score is different version 3 and version 4.  Thus, the scores cannot be compared.  
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